ViewMind

Alpine, NJFounded 201611–50 employeesviewmind.com

ViewMind is a neuroscience company developing non-invasive digital assessments that measure brain function through eye movements. Its technology supports precision neurology, preventive health, and clinical research through ViewMind NeuroScan and ViewMind Atlas.

Visit viewmind.com ↗

Founded: 2016
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

ViewMind’s recent activity reflects continued development of its eye-movement-based neurology platform and expansion of its operating team. On Feb 10, 2024, the company announced the appointment of Renata Afonso to lead LATAM expansion and global marketing initiatives, indicating an effort to extend commercial reach beyond its U.S. base. A Feb 13, 2024 industry article highlighted ViewMind’s digital biomarkers for neurocognitive disorders. The company also continued building its intellectual-property portfolio: patent activity was recorded on Oct 29, 2024 for a system and method for detecting neurological disorders and measuring related conditions, following filings in 2023 concerning disease-specific alterations and cognitive or motor-skill assessment. ViewMind appointed Denise Kelly as Vice President of Sales & Business Development on Feb 7, 2022, while executive and board appointments in August 2023 were intended to support growth. The company was acquired by Eqwow Ventures in June 2023.

Market position

ViewMind operates at the intersection of digital health, neurotechnology, diagnostics, and clinical research. Its differentiation is the use of non-invasive oculomotor measurements to derive digital biomarkers of cognitive and neurological function, rather than relying solely on questionnaires, conventional clinical observation, or costly imaging. The company’s offering spans a short brain-health assessment, eye-movement data analysis, physician-facing reporting, therapeutic-impact measurement, and longitudinal neurocognitive monitoring. NeuroScan is positioned for preventive-health and clinical assessment settings, while Atlas is oriented toward institutional research. The company cites more than 20 years of neuroscience research, over 80 peer-reviewed publications, 3,000-plus citations, and 25 patents, while the structured record lists five granted patents. Its ISO 13485-certified quality system is relevant for medical-device and clinical-research buyers.

Growth & opportunities

ViewMind’s trajectory shows a progression from founding in 2016 toward a more structured commercial and research organization. The 2022 appointment of Denise Kelly as Vice President of Sales & Business Development marked a move to strengthen commercialization. Executive and board appointments in August 2023, together with the June 2023 acquisition by Eqwow Ventures, represented additional organizational inflection points. In February 2024, Renata Afonso was appointed to spearhead LATAM expansion and global marketing, suggesting geographic and demand-generation ambitions. Product scope has expanded beyond screening to include longitudinal monitoring and therapeutic-impact measurement, while patent activity continued through October 2024. Growth therefore appears innovation- and organization-led, with commercial scale still difficult to measure.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes ViewMind distinct

reccy insights

What makes ViewMind distinct

01Measures brain function through the eyes using non-invasive oculomotor assessments.
02Built on 20 years of neuroscience research, with more than 80 peer-reviewed publications, 3,000-plus citations, and 25 patents.
03Offers distinct solutions for preventive-health clinics and institutional clinical research through NeuroScan and Atlas.
04Maintains an ISO 13485-certified quality-management system.
05Collaborates with research and healthcare institutions across multiple continents.

Technology & products6

Technology & products

Evaluation
An assessment conducted using a head-mounted display that tracks eye movements in response to visual stimuli to measure neurocognitive health.
Data Analysis
Patented ocular digital phenotyping uses statistical models to analyze eye-movement data and detect minor cognitive alterations or changes in motor function.
Report
A report generated from eye-movement data analysis that provides insights into a patient’s cognitive condition for physician review.
Brain Health Assessment
A non-invasive 15-minute test that evaluates cognitive and brain health by identifying ocular patterns associated with neurodegenerative diseases.
Therapeutic Impact Measurement
Objective evidence on the impact of drugs on cognitive health, supporting treatment selection through ocular digital phenotyping.
Neurocognitive Performance Monitoring
Longitudinal tracking of neurocognitive performance and brain changes to distinguish disease-related from age-related alterations.

Show all 6 products

+ 3 more: Brain Health Assessment, Therapeutic Impact Measurement, Neurocognitive Performance Monitoring

Recent updates1

Launches, partnerships and team changes from press coverage

Feb 7, 2022Team change
ViewMind appointed Denise Kelly as Vice President of Sales & Business Development.
prnewswire.com

About ViewMind

Products: Evaluation, Data Analysis, Report, Brain Health Assessment, Therapeutic Impact Measurement, Neurocognitive Performance Monitoring
Leadership: Gerardo Fernandez, Founder and CSOMark Edwards, Chief Executive Officer & Co-founderDenise Kelly, Vice President Sales & Business DevelopmentMatias Shulz, COO
Focus areas: Digital health, neuroscience, precision neurology, medical devices, diagnostics, clinical research, eye tracking, AI
Headquarters: Alpine, NJ
Founded: 2016
Employees: 11–50
Patents granted: 5 (Crunchbase)
Trademarks: 1